Comparative Pharmacology
Head-to-head clinical analysis: DELTA CORTEF versus TEXACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTA CORTEF versus TEXACORT.
DELTA-CORTEF vs TEXACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
TEXACORT (hydrocortisone) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, immunosuppressive, and metabolic effects.
Prednisolone (DELTA-CORTEF) typical adult dose: 5-60 mg orally once daily or in divided doses, depending on condition. For acute exacerbations: 20-60 mg orally daily. Route: oral. Frequency: once daily or divided.
50 mg intravenously every 6 hours as a single agent or in combination with other antineoplastic agents.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (mean ~2 hours) for prednisolone; clinical context: short-acting glucocorticoid, requires multiple daily dosing for sustained anti-inflammatory effect, adrenocortical suppression lasts approximately 1.25-1.5 days after discontinuation.
Terminal elimination half-life: 3-4 hours. In renal impairment, half-life may be prolonged up to 12 hours.
Renal: approximately 80-90% as unchanged drug and metabolites (primarily 20β-dihydrocortisone and other inactive conjugates); biliary/fecal: <10%.
Renal: 80-90% as unchanged drug and inactive metabolites; biliary/fecal: 10-20%.
Category C
Category C
Corticosteroid
Corticosteroid